0001213900-24-035721.txt : 20240424
0001213900-24-035721.hdr.sgml : 20240424
20240424140804
ACCESSION NUMBER: 0001213900-24-035721
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240419
FILED AS OF DATE: 20240424
DATE AS OF CHANGE: 20240424
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lowdell Mark William
CENTRAL INDEX KEY: 0001767037
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38793
FILM NUMBER: 24869601
MAIL ADDRESS:
STREET 1: THE OAK, WLX ROAD
CITY: BEAUMONT
STATE: X0
ZIP: CO16 0AT
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Inmune Bio, Inc.
CENTRAL INDEX KEY: 0001711754
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 475205835
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 225 NE MIZNER BLVD, SUITE 640
CITY: BOCA RATON
STATE: FL
ZIP: 33432
BUSINESS PHONE: 8589643720
MAIL ADDRESS:
STREET 1: 225 NE MIZNER BLVD, SUITE 640
CITY: BOCA RATON
STATE: FL
ZIP: 33432
4/A
1
ownership.xml
X0508
4/A
2024-04-19
2024-04-23
0
0001711754
Inmune Bio, Inc.
INMB
0001767037
Lowdell Mark William
C/O INMUNE BIO INC.
225 NE MIZNER BLVD., SUITE 640
BOCA RATON
FL
33432
0
1
1
0
Chief Scientific Officer
0
Common Stock
2024-04-19
4
P
0
14423
8.32
A
1510806
D
Common Stock Warrants (right to buy)
9.152
2024-04-19
4
P
0
14423
0.125
A
2024-04-24
Common Stock
14423
14423
D
The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $8.445, for an aggregate purchase price of $121,802.24 pursuant to a securities purchase agreement dated April 19, 2024. The warrants are exercisable immediately upon issuance until the earlier of (i) the two year anniversary of the initial exercise date or (ii) thirty trading days following the reporting of the top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the "Termination Date") but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock, such officers, directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the Warrant.
The original Form 4, filed on April 23, 2024 is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the transaction as an award in column 3 of Table I and column 4 of table II instead of a purchase. The reporting person purchased the securities in a registered direct transaction from the Company.
/s/ Mark William Lowdell
2024-04-24